TITLE

DENOSUMAB: A NEW TREATMENT OPTION FOR OSTEOPOROSIS

AUTHOR(S)
Tikoo, Deepika; Meenakshi, Gupta
PUB. DATE
April 2012
SOURCE
Professional Medical Journal;Mar/Apr2012, Vol. 19 Issue 2, p141
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Osteoporosis is the most common metabolic bone disease in developed countries. One of its major problems is the long term morbidity and poor quality of life of patients. Receptor activator of nuclear factor-κB, its ligand and osteoprotegrin pathway plays an important role in bone remodeling. Receptor activator of nuclear factor-κB interacts with receptor activator of nuclear factor-κB ligand leading to activation of osteoclasts. Denosumab, a fully monoclonal antibody to receptor activator of nuclear factor-κB ligand prevents its binding to receptor activator of nuclear factor-κB and can effectively suppress the bone loss in osteoporosis. Various clinical studies have shown that Denosumab has good efficacy in decreasing bone resorption and has a favourable safety profile also
ACCESSION #
76115826

 

Related Articles

  • A review of denosumab for the treatment of osteoporosis. Miyazaki, Tsuyoshi; Tokimura, Fumiaki; Tanaka, Sakae // Patient Preference & Adherence;2014, Vol. 8, p463 

    Osteoporosis is an age-related systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility. Bone remodeling involves two types of cells: osteoblasts and osteoclasts. Receptor activator of nuclear...

  • Denosumab Receives Conditional Approval from FDA Expert Panel.  // Internal Medicine Alert;10/16/2009 Supplement, p2 

    The article reports on the conditional approval given by the Food & Drug Administration (FDA) Expert Panel to the use of Denosumab human monoclonal antibody for the treatment of osteoporosis in the U.S.

  • Bone health status in Indian women. Khadilkar, Anuradha V.; Kajale, Neha A. // Indian Journal of Medical Research;Jan2013, Vol. 137 Issue 1, p7 

    The article discusses the importance of serum biomarkers on bone turnover (BTM) to evaluate bone health. It mentions the usefulness of such markers in the assessment of patients with metabolic bone disease. It notes that the BTM is capable of measuring the formation and the degradation of bone...

  • A call to action: developing and implementing a national action plan to improve bone health. Raisz, L. G.; Elderkin, A. L.; Schargorodski, L.; Hart, T.; Waldman, C.; King, T.; Noonan, A. S. // Osteoporosis International;Nov2009, Vol. 20 Issue 11, p1805 

    The author reflects on the national action plan to improve bone health in order to treat osteoporosis and other bone disorders. The author cites the report "Surgeon General's Report on Bone Health and Osteoporosis" which promotes awareness, diagnosis, prevention, and treatment of osteoporosis...

  • Severe hypercalcemia due to teriparatide. Karatoprak, Cumali; Kayatas, Kadir; Kilicaslan, Hanifi; Yolbas, Servet; Yazimci, Nurhan Aliye; Gümüskemer, Tolga; Demirtunç, Refik // Indian Journal of Pharmacology;Apr2012, Vol. 44 Issue 2, p270 

    Osteoporosis that is by far the most common metabolic bone disease, has been defined as a skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Anabolic therapy with teriparatide, recombinant human parathyroid hormone (PTH 1-34),...

  • Denosumab best value for osteoporosis in Belgium.  // PharmacoEconomics & Outcomes News;6/26/2010, Issue 606, p6 

    The article discusses research on the cost effectiveness of the monoclonal antibody denosumab compared with oral bisphosphonates for treating osteoporosis in postmenopausal women in Belgium, referencing a study by M. Hiligsmann and colleagues presented at the 2010 International Osteoporosis...

  • Os oste�citos s�o fundamentais na remodela��o �ssea! CONSOLARO, Alberto // Revista Cl�nica de Ortodontia Dental Press;fev/mar2012, Vol. 11 Issue 1, p124 

    The osteocytes are included in the mineralized bone matrix in gaps known as osteoplasts, with numerous cytoplasmic extensions in dozens of microscopic channels which intercomunicate, physically and biochemically, with the other cells in the cortical and trabeculae surfaces. Through the...

  • Pamidronate and Zoledronic Acid in the Treatment of Paget's Disease of Bone. Colina, Matteo; Ciancio, Giovanni; Trotta, Francesco // Clinical Medicine: Therapeutics;2009, Issue 1, p1451 

    Paget's disease of bone (PDB) is a condition characterized by excessive and abnormal bone remodelling. Due to a high rate of bone remodelling, bisphosphonates, and especially pamidronate and the newer zolendronate, are indicated in the treatment of PDB. The presence of asymptomatic, but active...

  • No evidence for disturbed COL1A1 and A2 expression in otosclerosis. Csomor, Péter; Liktor, Balázs; Liktor, Bálint; Sziklai, István; Karosi, Tamás // European Archives of Oto-Rhino-Laryngology;Sep2012, Vol. 269 Issue 9, p2043 

    Otosclerosis is a complex bone remodeling disorder of the human otic capsule that might be associated with various mutations of A1 and A2 alleles of type-I collagen. The study herein presented, investigates the possibilty of the genetic involvement of type-I collagen in the pathogenesis of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics